Show simple item record

dc.contributor.authorShannon, Emer
dc.contributor.authorConlon, Michael
dc.contributor.authorHayes, Maria
dc.date.accessioned2021-07-26T15:56:24Z
dc.date.available2021-07-26T15:56:24Z
dc.date.issued2021-06-23
dc.identifier.citationShannon, E.; Conlon, M.; Hayes, M. Seaweed Components as Potential Modulators of the Gut Microbiota. Mar. Drugs 2021, 19, 358. https://doi.org/10.3390/md19070358en_US
dc.identifier.urihttp://hdl.handle.net/11019/2510
dc.descriptionpeer-revieweden_US
dc.description.abstractMacroalgae, or seaweeds, are a rich source of components which may exert beneficial effects on the mammalian gut microbiota through the enhancement of bacterial diversity and abundance. An imbalance of gut bacteria has been linked to the development of disorders such as inflammatory bowel disease, immunodeficiency, hypertension, type-2-diabetes, obesity, and cancer. This review outlines current knowledge from in vitro and in vivo studies concerning the potential therapeutic application of seaweed-derived polysaccharides, polyphenols and peptides to modulate the gut microbiota through diet. Polysaccharides such as fucoidan, laminarin, alginate, ulvan and porphyran are unique to seaweeds. Several studies have shown their potential to act as prebiotics and to positively modulate the gut microbiota. Prebiotics enhance bacterial populations and often their production of short chain fatty acids, which are the energy source for gastrointestinal epithelial cells, provide protection against pathogens, influence immunomodulation, and induce apoptosis of colon cancer cells. The oral bioaccessibility and bioavailability of seaweed components is also discussed, including the advantages and limitations of static and dynamic in vitro gastrointestinal models versus ex vivo and in vivo methods. Seaweed bioactives show potential for use in prevention and, in some instances, treatment of human disease. However, it is also necessary to confirm these potential, therapeutic effects in large-scale clinical trials. Where possible, we have cited information concerning these trialsen_US
dc.description.sponsorshipH2020 Marie Skłodowska-Curie Actions
dc.language.isoenen_US
dc.publisherMDPI AGen_US
dc.relation.ispartofseriesMarine Drugs;vol 19
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectseaweeden_US
dc.subjectprebioticsen_US
dc.subjectgut microbiotaen_US
dc.subjectpolysaccharidesen_US
dc.subjectpolyphenolsen_US
dc.subjectpeptidesen_US
dc.subjectcolonic fermentationen_US
dc.subjectshort chain fatty acidsen_US
dc.subjectbioaccessabilityen_US
dc.subjectsimulated gastrointestinal and fermentation digestion modelsen_US
dc.titleSeaweed Components as Potential Modulators of the Gut Microbiotaen_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.3390/md19070358
dc.identifier.piimd19070358
dc.contributor.sponsorMarie Skłodowska-Curieen_US
dc.contributor.sponsorGrantNumber754380.en_US
dc.source.volume19
dc.source.issue7
dc.source.beginpage358
refterms.dateFOA2021-07-26T15:56:25Z
dc.source.journaltitleMarine Drugs
dc.identifier.eissn1660-3397


Files in this item

Thumbnail
Name:
marinedrugs-19-00358-v5 (1).pdf
Size:
819.9Kb
Format:
PDF
Description:
main article

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International